


Cite this: *RSC Adv.*, 2018, 8, 39477

Multiple 3D-QSAR modeling, e-pharmacophore, molecular docking, and *in vitro* study to explore novel AChE inhibitors†

Srabanti Jana,  Ankit Ganeshpurkar  and Sushil Kumar Singh *

Ligand-based and energy-optimized structure-based approaches were considered to obtain excellent candidates as AChE inhibitors. The known AChE inhibitors were utilized to develop a pharmacophore hypothesis, HPRRR and X-ray crystallographic structures of AChE were used to produce three e-pharmacophore hypotheses viz. AHRRR, AHRR, and DHRR. Based on *in silico* approaches, we came across eight structurally diverse hits as non-competitive AChE inhibitors with good ADME properties. The best four hits, ZINC20592007, ZINC05354646, ZINC20649934, and ZINC39154782 were non-toxic, neuroprotective, and were selective AChE inhibitors (IC₅₀ values 482 ± 1.88 nM, 580 ± 1.63 nM, 854 ± 2.65 nM, and 636 ± 1.79 nM respectively). The hits showed non-competitive inhibition of AChE at PAS site with attractive K_i values (0.21 ± 0.027 μM, 0.27 ± 0.064 μM, 0.3 ± 0.018 μM, and 0.28 ± 0.032 μM for ZINC20592007, ZINC05354646, ZINC20649934, and ZINC39154782 respectively), and increased the cholinergic activity as well as inhibited Aβ aggregation.

Received 3rd October 2018
Accepted 16th November 2018

DOI: 10.1039/c8ra08198k

rsc.li/rsc-advances

Introduction

Acetylcholinesterase (AChE), a 3.5 kDa protein, is a member of the carboxylesterase family with an α/β-hydrolase fold.¹ The leading role of AChE is the hydrolysis of synaptic acetylcholine (ACh) and regulation of cholinergic neurotransmission in the body. It also plays a pivotal role in neuritogenesis, synaptogenesis, amyloidosis, dopamine neuron activation, regulation of apoptosis, nerve regeneration, hematopoiesis, and lymphocyte activation.^{2,3} The *in vitro* and *in vivo* exercises explain the relationship between amyloid precursor protein (APP) processing and cholinergic activation through muscarinic and nicotinic receptors.^{4,5}

Structurally, AChE consists of 'large central mixed β-sheets' surrounded by '15 α-helices'.⁶ The catalytic anionic site (CAS) is located at the bottom of a narrow gorge of AChE consisting of esteratic site (Ser203, Glu334, and His447) and anionic site (Trp86). Another site, named as peripheral anionic site (PAS) (consisting of Tyr72, Asp74, Tyr124, Trp286, and Tyr341 residues) is 20 Å from the catalytic center. The aromatic residue's

ring creates 40% surface of the gorge and is located in the loop, thus presenting greater conformational flexibility. The Trp86 residue forms π-cation interaction with quaternary nitrogen of the ACh along with Phe 338.⁷ The PAS of AChE acts as an adhesion site to non-amyloidogenic conformer of Aβ leading to its conformational change to produce amyloid fibrils.⁸ The Trp286 at the PAS site mimics response of the whole enzyme on amyloid formation.⁹ Further, AChE-Aβ complexes induce neurotoxicity and trigger more neurodegeneration than Aβ peptide alone. Thus, designing AChE inhibitor (AChEI) that blocks PAS of the enzyme will prevent Aβ aggregation as well as enhance cholinergic transmission for treating Alzheimer's disease (AD).

Both, β-amyloid protein (Aβ) and abnormally hyperphosphorylated tau (P-tau) can influence AChE overexpression in AD.¹⁰ The improvement of cholinergic transmission by using AChEI may boost cognitive impairment of patients with schizophrenia,^{11,12} and Parkinson's disease (PD).¹³ The acetylcholine receptors at neuromuscular junction are reduced in myasthenia gravis (MG),¹⁴ and AChEIs are considered essential for the treatment of MG. AChEIs can enhance cholinergic up-regulation by weakening the effect of neuroinflammation *via* immunocompetent cells expressing α-7-acetylcholine receptor (AChR).¹⁵

Butyrylcholinesterase (BuChE) level is increased by up to 2-fold during mild to moderate AD,¹⁶ and causes an imbalance between synthesis or synaptic release of ACh and its enzymatic hydrolysis. Therefore, AChEIs with BuChE inhibition property may provide better therapeutic value in neurological disorders.

Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, India. E-mail: sksingh.phe@iitbhu.ac.in; Tel: +91-542-6702736/49

† Electronic supplementary information (ESI) available: Results of DFT study, graphs, and calculations of enzyme inhibition study, experimental procedure, and calculations of PAMPA study; Structures of known AChE inhibitors with test and training sets for development of pharmacophore; identified virtual hits alignment with their pharmacophores and interaction images of hits. See DOI: 10.1039/c8ra08198k




Fig. 1 Flowchart of hit identification based on ligand-based and structure-based pharmacophore models.

The drug discovery process is time-consuming and cumbersome, but the use of *in silico* approaches helps to identify better hits and scaffolds for a target. The pharmacophore modeling is a mathematical modeling technique which may help in the quick prediction of hits. The combination of ligand-based and structure-based pharmacophore models help in better productivity of outcome.¹⁷ Earlier researchers attempted to develop pharmacophore models and utilized them for virtual screening of database molecules to find new AChE inhibitors.^{18–23}

Present work combines both ligand-based (3D-QSAR) and energy optimized structure-based pharmacophore (e-pharmacophore) approaches for virtual screening of free 'ZINC15' database molecules. The hits, as AChE inhibitors, were recognized by utilizing HTVS and molecular docking studies of pharmacophore matched compounds after removal of pan-assay interference compounds (PAINS).²⁴ The workflow of hit identification based on ligand-based 3D-QSAR and structure-based e-pharmacophore is explicit in Fig. 1.

The *in vitro* studies *viz.* enzyme inhibitions (AChE & BuChE), enzyme kinetics (AChE), propidium iodide displacement from AChE, parallel artificial membrane permeability assay for blood–brain barrier (PAMPA-BBB), effects on cell viability and neuroprotectivity against apoptosis triggered by L-glutamate, approved and validated the outcome from the *in silico* study.

Results and discussion

Development of ligand-based pharmacophore model

Atom-based 3D-QSAR model was developed by using 142 datasets, which was divided into actives, inactives, and moderately

actives. Total 163 hypotheses were generated and the best pharmacophore hypothesis, HPRRR, was selected on the basis of good survival activity (3.7), survival-inactive score (2.22), vector score (0.998), volume (0.862), selectivity (2.576), energy scores, best active alignment, and number of site matches (Table 1).

Hypothesis HPRRR: one hydrogen-bond acceptor, one positive ionizable group, and three aromatic rings showed the highest survival score. The developed 3D-QSAR pharmacophore model was statistically validated internally and externally to exhibit reliable predictions. We randomly selected 100 compounds in the training set and 42 in the test set to generate 3D-QSAR model. The statistical parameters were obtained by 'leave one out' (LOO) method and by partial least-square (PLS) analyze. HPRRR hypothesis showed better predictive ability, with PLS factor 5 than others (Table 2).

Validation of ligand-based pharmacophore model

At PLS factor 5, hypothesis HPRRR showed low SD value of 0.225, RMSE of 0.409, and *P* value of 1.13×10^{-64} , and higher *R*² of 0.961 for the training set, and good *Q*² of 0.729; Person-*R* of 0.857; *F* value of 465.7 for the test set. Therefore, HPRRR model had good predictivity at PLS factor 5 and was taken for further pharmacophore-based screening of database molecules. The pharmacophoric features of 3D-QSAR hypothesis are sketched in Fig. 2. The distance between pharmacophores was within the range of 2.174–11.329 Å (Table 3).

All the parameters for external validation of ligand-based pharmacophore model helped to select best model (Table 4). The correlation coefficient (*r*²) value of 0.922, cross-validation

Table 1 The 3D-QSAR pharmacophore hypothesis with various scores

Hypothesis ^a	Survival score	Survival-inactive score	Site score	Vector score	Volume	Selectivity
HPRRR	3.7	2.22	0.84	0.998	0.862	2.576

^a H, hydrogen bond donor; P, positively ionizable group; and R, aromatic ring.



Table 2 PHASE 3D-QSAR and PLS statistics for internal validation of hypothesis

Hypothesis	PLS factor	SD ^a	R ^{2b}	F ^c	P	Stability	RMSE ^d	Q ^{2e}	Pearson-R ^f
HPRRR	1	0.735	0.570	129.7	1.204×10^{-19}	0.933	0.651	0.314	0.588
	2	0.482	0.817	216.5	1.706×10^{-36}	0.843	0.480	0.627	0.797
	3	0.376	0.890	257.8	8.733×10^{-46}	0.770	0.468	0.646	0.813
	4	0.288	0.936	347.5	8.721×10^{-56}	0.702	0.437	0.691	0.834
	5	0.225	0.961	465.7	1.13×10^{-64}	0.678	0.409	0.729	0.857

^a Standard deviation of the regression. ^b The square of correlation coefficient. ^c Variance ratio. ^d Root-mean-square error. ^e Squared Q value for the predicted activities. ^f Correlation between the predicted and observed activities for the test set.




Fig. 2 3D-QSAR pharmacophore hypotheses and structure-based pharmacophores models with their respective crystal structures. (A) H-bond acceptor, pink sphere containing arrow; (D) H-bond donor, sky blue sphere with arrow; (H) hydrophobic group, green sphere; (P) positive ionizable group, violet sphere; (R) aromatic ring, yellow circle.

coefficient (r_{cv}^2) value of 0.919, square of correlation coefficient value using the LOO method, ($R_{m(LOO)}^2$), of 0.834, also helped to consider 3D-QSAR model as a better predictive model. The slopes of regression lines through origin (K and K' value) and substantial values of correlation coefficients (R_0^2 and $R_0'^2$) were obtained from observed activity *versus* predictive activity plots (Fig. 3). The values were also within the limits and encouraged the model predictivity.

Development of energy-optimized structure-based pharmacophore

Total three human AChE (hAChE) crystal structures with a resolution between 2.0 Å and 2.35 Å and potent AChE inhibitory activity (IC_{50} from 5.3 to 7 nM and K_i 1.7 to 700 nM) were

selected for developing e-pharmacophore. Protein preparation wizard was used to prepare the proteins with an OPLS_2005 force field. After refinement, the protein structures with ligand interaction showed that donepezil (cocrystal of 4EY7) interacted with Trp86, and TRP286 by a pi-pi stacking, H-bond interacted with Phe295, and pi-cationic with Phe338 residue. The dihydrotanshinone I (cocrystal of 4M0E) interacted with TRP286 by a pi-pi stacking, H-bond interaction was with Phe295; and teritrem B (cocrystal of 4M0F) interacted with TRP286 by a pi-pi stacking and H-bond interaction was with Tyr124 at the PAS site (Fig. 4).

The refined cocrystal ligands were redocked onto the respective prepared protein structures to generate energy-optimized structure-based pharmacophore (e-



Table 3 Distance between features of 3D-QSAR hypotheses and e-pharmacophores

Pharmacophore model ^a	Distance from A to H (Å)	Distance from A to R (Å)	Distance from H to H (Å)	Distance from H to P (Å)	Distance from H to R (Å)	Distance from P to R (Å)	Distance from R to R (Å)	Distance from D to H (Å)	Distance from D to R (Å)
3D-QSAR-HPRRR				4.703	3.205	6.419	2.174		
					4.45	8.05	9.409		
					7.968	3.773	11.328		
4EY7-AHHRR	3.532	3.796	3.917		2.303		11.435		
	4.425				9.214				
		9.803			6.021				
					5.863				
4M0E-AHRR	3.576	5.102			4.844		2.463		
		6.36			7.105				
4M0F-DHRR					5.054		4.288	2.816	3.495
					8.549				7.135

^a Type of model written with pharmacophores; PDB used for the respective e-pharmacophore model.

Table 4 External validation parameters for 3D-QSAR

External validation parameters	HPRRR	Limitations
r_{cv}^{2a}	0.919	$r_{cv}^2 > 0.5$
r^{2b}	0.922	r^2 close to 1
k value ^c	0.990	$0.85 \leq k \leq 1.15$
K' value ^d	1.008	$0.85 \leq k \leq 1.15$
R_0^{2e}	0.916	Close to r^2
R_0^{2f}	0.921	Close to r^2
$R_{m(LOO)}^{2g}$	0.834	$R_{m(LOO)}^2 > 0.5$
r_{pred}^{2h}	0.738	$r_{pred}^2 > 0.5$

^a Cross-validated coefficient. ^b Correlation coefficient between actual and predicted values. ^c Slope values of regression lines. ^d Slope values of regression lines. ^e Correlation coefficients for regression lines through origin. ^f Correlation coefficients for regression lines through origin. ^g Modified squared correlation coefficient using LOO method. ^h Predictive correlation coefficient value.




Fig. 3 Plot of predicted pIC_{50} versus observed pIC_{50} of AChE inhibitors developed by model HPRRR with regression lines (original regression lines represented in green break line and regression lines with intercept zero in purple break line).

pharmacophore). The root-mean-square deviation (rmsd) was less than 1 Å for all the three cocrystal ligands. The e-pharmacophore hypotheses were generated by mapping Glide XP energetic terms onto pharmacophore sites, which were calculated from the structural and energy information between

protein and ligand. Initially, the numbers of pharmacophore sites were set up to 10 for each of crystal structures for pharmacophore generation, but numbers of pharmacophore sites were selected, for the best hypothesis, on the basis of validation parameters. The total number of pharmacophore sites for each cocrystal ligand before energy-based site selection and selected sites for hypothesis generation for the three crystal structures with pharmacophoric feature scores are given in Table 5. The e-pharmacophore models generated were AHRR with 5 sites from 4EY7, AHRR with 4 sites from 4M0E, and DHRR with 4 sites from 4M0F crystal structure (Fig. 2). In these pharmacophore modeling, A stranded for H-bond acceptor, D for H-bond donor, H for hydrophobic group, R for aromatic ring. The distance between e-pharmacophore features was within range of 2.303–11.435 Å (Table 3).

Validation of energy-optimized structure-based pharmacophore

The database, consisting of 1053 compounds using 1000 drug-like decoys and 53 known AChE inhibitors, was utilized for e-pharmacophore validation. We evaluated enrichment factor (EF) and Goodness of hit score (GH) utilizing Güner-Henry scoring method To validate the e-pharmacophores (Table 6). The values of GH over 0.5 and EF higher than 10, ensured the suitability of pharmacophores for further pharmacophore-based virtual screening.

Pharmacophore matched screening and removal of pan-assay interference compounds (PAINS)

Pharmacophore matched molecules were separated out from the total 3530990 ZINC15 database compounds (without known AChE inhibitors) by utilizing advance pharmacophore screening option of PHASE. The fitness value is a measure of how well the ligand fits with the pharmacophore. The hits with high fitness value of more than 1.5 are probably very active inhibitors. We employed the validated three e-pharmacophores, and one ligand-based pharmacophore to screen the database of 2000 AChE inhibitor molecules by each model.






Fig. 4 Crystal structures of AChE with cocrystal ligands (purple color) and bonding interactions.

Table 5 e-Pharmacophore hypotheses with features scores

PDB	No. of possible site	No. of accepted site	Hypotheses ^a	Pharmacophore features with score
4EY7	6	5	AHHRR	H7: −1.64, H6: −1.5, R10: −1.48, R9: −1.2, A3: −0.73
4M0E	4	4	AHRR	A3: −1.7, R7: −1.62, H4: −1.5, R8: −1.13
4M0F	7	4	DHRR	R19: −1.5, D11: −1.49, R20: −1.3, H15: −0.66

^a A, H-bond acceptor; D, hydrogen bond donor; H, hydrophobic group; P, positively ionizable group; R, aromatic ring.

Table 6 Validation of e-pharmacophores with the Güner–Henry scoring method using a dataset consisting of total 1053 compounds with 53 total actives compounds

Parameters	4EY7	4M0E	4M0F
Ht ^a	74	69	71
Ha ^b	41	37	43
EF ^c	11.008	10.654	12.033
GH ^d	0.589	0.558	0.639

^a Total hits. ^b Active hits. ^c Overall enrichment factor. ^d Goodness of hit score.

The reactivity towards proteins to develop poor potentiality or known toxicity of molecules, *i.e.*, PAINS was removed from pharmacophore matched compounds by using RDKit, ZINC, and FAF-Drugs4 server. Only less than 1% of PAINS compounds were removed and mild PAINS were ignored for virtual screening.

High throughput virtual screening (HTVS) and molecular docking

High throughput screening of PAINS removed pharmacophore matched database and was a fruitful resource for initial hit identification. The number of hits from pharmacophore-based virtual screening and process of selection with their respective PDB are presented in Table 7.

Molecular XP docking was performed for all the outcome HTVS retrieves with 4M0E crystal structure to compare docking

scores of hits with reference donepezil. We found that 55 molecules were having docking score more than −9.0. Finally, eight compounds with structural diversity, PAINS free (except ZINC20592007, a PAINS-ok molecule), better docking scores (−12.87 to −10.74) and Glide energies (−56.48 to −42.16 kcal mol^{−1}) than donepezil were selected for further studies (Table 8). The hits outcome with respect to pharmacophore models are listed in ESI (Table S1†). The protein–ligand interactions with types of interactions and interacting residues with hits and donepezil are included in Table 8. The chemical structures of hits are sketched in Fig. 5 and ligand–protein interactions are pictured in Fig. 6; hits are represented in yellowish green, interacting amino acid residues of protein in gray, H-bond in red, pi-cationic interaction in green and pi–pi stacking in cyan color. The presence of more hydroxyl, keto, secondary amine and nitrogen-containing hetero aromatics in hits were responsible for formation of hydrogen bond and more docking score than donepezil.

The hits mainly bind at PAS site of AChE through H-bond interactions with Phe295, Tyr337, and Phe338 residues (within 1.8–2.3 Å bond distance), pi–pi stacking with Trp286, His 287, Phe297, and Tyr341 residues (within 3.8–5.1 Å distance), and pi-cationic or salt bridge interactions with Asp74, Tyr341, and Trp286 residues (within 1.9–5.6 Å distance). Keto group of all hits, except ZINC77161317 and ZINC39154782 were formed H-bonding with Phe295 and Ser293, were formed hydrogen bonding with Phe295 residue of protein. Aromatic group of hits were produced π – π stacking interaction with Trp286, except ZINC39154782 interacting with Phe297.



Table 7 Number of compounds retrieved at each stage of screening of dataset

Pharmacophore models	PDB	HTVS hits	SP hits	XP hits	No. of selected hits
AHHRR	4EY7	1991	200	20	1
AHRR	4M0E	1873	199	19	2
DHRR	4M0F	1993	200	20	2
HPRRR	4M0F	1945	200	20	3

Table 8 Hit molecules with their Glide docking score, number of H-bonds, interaction with essential amino acids, IFD docking score, and AutoDock binding energy

Title	Glide docking score	H-bond	Glide energy	Residue interactions	MM-GBSA- ΔG_{bind}	IFD docking score	AutoDock binding energy
ZINC72451013	-12.87	3	-51.63	Asp74 ^a , Phe295 ^b , Arg296 ^b , Tyr337 ^b , Tyr341 ^c	-65.17	-11.53	-10.34
ZINC20649934	-12.65	2	-50.50	Asp74 ^a , Trp286 ^c , Phe295 ^b , Tyr337 ^b , Tyr341 ^d	-94.16	-10.77	-11.69
ZINC05354646	-11.93	1	-42.16	Trp286 ^{c,d} , Phe295 ^b	-73.30	-12.64	-9.85
ZINC79331983	-11.40	4	-54.98	Asp74 ^{a,b} , Phe295 ^b , Tyr337 ^b	-79.39	-11.09	-10.65
ZINC20592007	-11.26	2	-47.79	Tyr72 ^b , Trp286 ^{c,d} , His287 ^c , Phe295 ^b	-79.10	-12.78	-10.77
ZINC77161317	-11.02	1	-51.02	Trp286 ^d , Phe295 ^b , Phe297 ^c	-69.09	-12.699	-9.75
ZINC58160603	-10.93	1	-49.16	Trp286 ^d , Phe295 ^b	-80.61	-11.85	-9.32
ZINC39154782	-10.74	3	-49.28	Asp74 ^{a,b} , Try124 ^c , Ser293 ^b , Tyr337 ^{c,b} , Tyr341 ^d , Phe297 ^c , Phe338 ^c	-76.11	-11.88	-10.54
Donepezil	-8.24	1	-43.89	Tyr124 ^d , Trp286 ^c , Phe295 ^b , Phe338 ^d	-62.30	-8.91	-9.64

^a Salt bridge. ^b H-bond interaction. ^c Pi-Pi stacking. ^d Pi-cation interaction.




Fig. 5 Structures of final hits with zinc database ids.

Induced fit docking

The IFD scores of hits were close to the Glide XP docking scores (Table 8). The conformations generated from the IFD were little different from the docked poses produced from the rigid receptor docking. The Glide-based model gave an RMSD of 5.2 Å when compared to the native pose in the crystal structure. The IFD docking pose and score were supported by the binding positions, affinity, and stability of hits.

Calculation of prime MM-GBSA

To predict the binding mode and binding free energy (ΔG_{bind}), the Prime MM-GBSA simulation was calculated for AChE-hits and AChE-cocrystal ligand complexes utilizing Maestro 10.1 (Table 8). All the hits showed better ΔG_{bind} , and ZINC20649934 provided highest ΔG_{bind} , -94.16 kcal mol⁻¹. The binding free energy determination, based on Prime MM-GBSA, established the stability of AChE-hits complexes.

Docking with AutoDock

The AutoDock binding energy of the hits was calculated and presented in Table 8. The binding energy of final eight hits was between -9.32 to -11.69 kcal mol⁻¹. The prediction of results was fully supported Glide XP docking and IFD results (Table 8). All the hits displayed similar binding affinity and docking pose with 4M0E utilizing AutoDock and Glide (ESI, Fig. S1 and S2†).






Fig. 6 Docking poses of ZINC72451013, ZINC20649934, ZINC05354646, ZINC79331983, ZINC20592007, ZINC77161317, ZINC58160603, and ZINC39154782 with AChE crystal structure; hits represented in yellowish green, residues in gray, H-bond in red, pi-cationic interaction in green and pi-pi stacking in cyan color.

Predicted ADME properties

The predictions of drug-likeness and pharmacokinetics including absorption, distribution, metabolism, and excretion (ADME) were performed by utilizing QikProp tools of Maestro,

Schrödinger. We evaluated physiochemically descriptors and pharmaceutically relevant properties of hits to analyze drug-gable properties (Table 9). All the hit molecules showed a good partition coefficient (QP log Po/w) values (1.6 to 3.854), which



Table 9 Hit molecules with their physiochemical descriptors determined by Qikprop tools

Compound id ^a	QP log Po/w ^b	QP log S ^c	QP log HERG ^d	QPPCaco ^e	QPPMDCK ^f	QP log K _p ^g	% of human oral absorption ^h	Rule of five ⁱ
ZINC72451013	3.586	−4.62	−6.76	249.141	121.859	−4.273	90.835	0
ZINC20649934	2.619	−3.37	−6.631	529.903	1193.73	−3.718	91.036	0
ZINC05354646	1.627	−1.92	−5.112	553.223	288.626	−4.359	85.562	0
ZINC79331983	3.854	−4.37	−5.055	1879.796	978.659	−3.407	100	0
ZINC20592007	3.448	−4.50	−6.75	199.231	173.105	−4.22	88.291	0
ZINC77161317	1.6	−2.38	−5.559	79.257	56.117	−4.617	70.301	0
ZINC58160603	2.674	−3.38	−6.619	393.786	546.198	−3.897	89.056	0
ZINC39154782	3.311	−5.64	−6.286	406.683	187.069	−2.709	93.035	0

^a Zinc database compound id. ^b QP log Po/w for octanol/water (−2.0 to 6.5). ^c QP log S: predicted aqueous solubility, S in mol dm^{−3} (−6.5 to 0.5). ^d log HERG: HERG K⁺ channel blockage (<−5). ^e Apparent Caco-2 cell permeability (nm s^{−1}) (<25 poor, >500 great). ^f Apparent MDCK permeability (nm s^{−1}) (<25 poor, >500 great). ^g QP log K_p: skin permeability. ^h % human oral absorption (>80% is high and <25% is poor). ⁱ Rule of five: no. of violations of Lipinski's rule of five (0 is good and 4 is bad).

Table 10 Inhibitory activity on AChE (electric eel) and BChE (horse serum) and propidium competition assay results

Compounds	IC ₅₀ AChE ^a (nM)	IC ₅₀ BChE ^a (nM)	Selectivity ^b (AChE/BChE)	Propidium displacement (%)		
				0.24 μM	1 μM	3 μM
ZINC20592007	482 ± 1.88	23954 ± 5.69	49.7	44	70	100
ZINC05354646	580 ± 1.63	147424 ± 6.66	254.2	0	42	57
ZINC20649934	854 ± 2.65	148654 ± 6.24	174.1	0	25	58
ZINC39154782	636 ± 1.79	128064 ± 5.13	201.4	29	58	100
Donepezil	24 ± 0.29	7421 ± 2.00	309.2	0	0	0

^a Each assay was repeated three times independently. ^b Selectivity for AChE = [IC₅₀ (BuChE)]/[IC₅₀ (AChE)].

were critical for absorption and distribution of drugs. Factor QPPCaco, indicating permeability of these hits, was in the range of 79.257 to 1879.796, where QPPCaco was a predicted apparent Caco-2 cell permeability in nm s^{−1} value, a key factor for the estimation of cell permeability in biological membranes.

All the hits successfully passed the entire pharmacokinetic requirements for a drug-like compound and were within the acceptable range as defined for human use. Overall, the percentage of human oral absorption for the compounds were between 70.301 to 100%, their water solubility (QP log S) ranged between −1.919 to −6.373, pMDCK (cell permeable parameter) values were between 56.117 to 1193.73, skin permeability (log K_p) values were within −2.709 to −4.898; p log HERG (K⁺ channel blockage) values were less than −5. Additional parameters *i.e.*, molecular weight, H-bond donors, H-bond acceptors, and log P according to Lipinski's rule of five, were also evaluated for their drug-like behavior. Thus, hits with better binding interaction and good predicted pharmacokinetic properties were considered for *in vitro* studies.

Density functional theory

The HOMO and LUMO of chemical compounds are crucial indicators of their reactivity and also stability of ligand–receptor interactions.²⁵ The stability of interactions is inversely correlated to energy gap between HOMO and LUMO orbitals. The orbital energy of all energetically stable hit molecules was calculated by using a DFT method. The high value of HOMO energy is likely to indicate the tendency of molecule to donate electrons to an appropriate acceptor molecule with LUMO. The correlation of HOMO energies with IC₅₀ data suggested that the HOMO of inhibitor might transfer its electrons to less energy, LUMO, of some amino residues in the active site of the enzyme. The calculated DFT properties of all hits are given in ESI (Table S2†). The HOMO–LUMO energy gaps of hits were minimal, and between −0.182 to −0.012 eV. Lesser HOMO–LUMO energy gap facilitated electron(s) density exchanging properties or encouraged some interaction(s). The mean ESP indicated electron density distribution around nuclei of the molecules and was

Table 11 Permeability, Pe (10^{−6} cm s^{−1}) determined by BBB-PAMPA study of hit compounds

Compounds	Pe _(exp) ^a [10 ^{−6} cm s ^{−1}]	Pe _(actual) ^a [10 ^{−6} cm s ^{−1}]	Prediction ^b
ZINC20592007	5.00 ± 0.3	5.7 ± 0.20	CNS+
ZINC05354646	7.8 ± 0.25	9.39 ± 0.36	CNS+
ZINC20649934	3.74 ± 0.136	5.45 ± 0.79	CNS+
ZINC39154782	4.69 ± 0.2	5.29 ± 0.31	CNS+

^a Data expressed as mean ± SEM of three independent experiments. ^b CNS + indicates good passive CNS permeation.






Fig. 7 Michaelis–Menten kinetics curve resulting from velocity of AChE activity with different substrate concentrations (0.15–1.15 μM) in absence and presence of 0.25, 0.5 and 1 μM of ZINC20592007.




Fig. 8 Michaelis–Menten kinetics curve resulting from velocity of AChE activity with different substrate concentrations (0.15–1.15 μM) in absence and presence of 0.25, 0.5 and 1 μM of ZINC05354646.

between -0.22 to $1.89 \text{ kcal mol}^{-1}$. The ESP data indicated that most of the hits contained both low and high electron density sites in a molecule. The upper and low electron density regions may correspond to the hydrogen bonding between the hits and enzyme.

In silico AChE selectivity study

We performed Glide XP docking study against BuChE by utilizing 4BDS crystal structure to estimate selectivity of hits




Fig. 9 Michaelis–Menten kinetics curve resulting from velocity of AChE activity with different substrate concentrations (0.15–1.15 μM) in absence and presence of 0.5, 1 and 2 μM of ZINC20649934.




Fig. 10 Michaelis–Menten kinetics curve resulting from velocity of AChE activity with different substrate concentrations (0.15–1.15 μM) in absence and presence of 0.5, 1 and 2 μM of ZINC39154782.

towards AChE. All the hits had BuChE binding affinity with more selectivity towards AChE (ESI Table S3[†]). The hit ZINC05354646 showed lowest Glide docking score (-5.66), and next lowest score compound was ZINC20649934 (-5.85) against BuChE crystal structure, 4BDS. The BuChE binding property of hits with AChE inhibition improved the therapeutic property of hits for cholinergic activity. The hits had moderate BuChE binding affinity which may improve cholinergic activity.

In vitro inhibition of AChE and BuChE

Four hits (ZINC20592007, ZINC05354646, ZINC20649934, and ZINC39154782) were selected, based on Glide docking score, AutoDock energy, AChE selectivity, PAS site selectivity, ADME properties, and interesting structural features for further *in vitro* studies. ZINC20592007 contains a 2,3-dihydrocyclopenta[*c*]chromen-4(1*H*)-one fused nucleus, which is PAINS-ok (mannich-A type) molecule. ZINC05354646, a 2,3,9,10-tetrahydro-8*H*-cyclopenta[3,4]chromeno[6,7-*e*][1,3]oxazin-4(1*H*)-one fused compound, is PAINS free with similar scaffold of ZINC20592007. ZINC20649934 has thieno[2,3-*d*:4,5-*d'*]dipyrimidin-4(3*H*)-one nucleus with attached morpholine ring to ethylene linker. ZINC39154782 contains 1,2,4-triazin-5(6*H*)-one with indole ring attached through an ethyl amino linker (Fig. 5).

The selected hits were evaluated for their anti-cholinesterase (anti-ChE) activity. AChE and BuChE inhibition activities were evaluated by the method described by Ellman,²⁶ wherein donepezil was used as reference standard. Compound ZINC20592007 exhibited higher AChE inhibitory activity than ZINC05354646, ZINC20649934, and ZINC39154782 [IC_{50} values (nM) of 482 ± 1.88 , 580 ± 1.63 , 854 ± 2.65 , and 636 ± 1.79 , respectively (Table 10)]. All the hits has selective AChE inhibitory activity than BuChE enzyme (Table 10). The half maximal enzyme inhibitory concentration (IC_{50}), a measure of potency of hits inhibiting AChE and BuChE, was calculated by constructing a dose-response curve (ESI, Fig. S3[†]) by utilizing GraphPad Prism 5.0.

The mechanism of AChE enzyme inhibition of the four hits was determined by an enzyme kinetic study. Lineweaver–Burk reciprocal plots were generated by plotting reciprocal of reaction rates and reciprocal of substrate concentrations using



Table 12 Cell viability, and neuroprotection of hit molecules in human neuroblastoma SH-SY5Y cell line

Compounds	Cell viability ^a (%)		Neuroprotection ^b (%)
	50 μ M	100 μ M	25 μ M
ZINC20592007	98.0 \pm 0.34	95.3 \pm 0.32	18.2 \pm 0.086
ZINC05354646	90.2 \pm 0.39	88.7 \pm 0.77	20.0 \pm 0.061
ZINC20649934	94.8 \pm 0.49	93.0 \pm 0.45	67.8 \pm 0.013
ZINC39154782	98.6 \pm 0.55	97.1 \pm 0.08	26.3 \pm 0.077

^a Percentage cell viability of SH-SY5Y cells exposed at relatively high concentrations (50 μ M and 100 μ M) of test compounds. ^b Percentage neuroprotection of SH-SY5Y cells at relatively lower concentrations (25 μ M) of test compounds against L-glutamate (100 μ M).

different concentrations of hit molecules. Michaelis–Menten kinetics curve resulting from velocity of AChE activity with varying concentrations of substrate (0.15–1.15 μ M) in absence and presence hit molecules (0.25, 0.5 and 1 μ M of ZINC20592007 and ZINC05354646, and 0.5, 1, and 2 μ M for ZINC20649934, and ZINC39154782) are shown in Fig. 7, 8, 9, and 10 respectively. The K_i values of hits were determined by Yonetani–Theorell method from Lineweaver–Burk plots and presented in ESI as Fig. S4–S7† for ZINC20592007, ZINC05354646, ZINC20649934, and ZINC39154782 respectively.

The plots revealed that with increasing the concentrations of inhibitor, an increase in slope (decreased V_{\max}) and the intercept (higher K_m) occurred. The lower apparent value of V_{\max} in Michaelis–Menten plot to increase, decrease, or leave




Fig. 11 RMSD plot (donepezil–AChE, ZINC20592007–AChE, and ZINC20649934–AChE complexes) of RMSD values for protein on the left Y-axis and for ligand these values were displayed on right Y-axis; protein backbone in green color, and ligand in maroon color.



unaffected apparent value of K_m , (ESI, Table S4†), indicated as non-competitive inhibitor on the kinetic constants. The double reciprocal Lineweaver–Burk displayed a nest of lines that intersect at a point other than y-axis, and intersecting lines converge to the left of y-axis, and below the x-axis, *i.e.*, $\alpha < 1$, and indicating that the inhibitor binds with greater affinity to the enzyme–substrate (ES) complex or subsequent species. The calculated inhibitor constant (K_i) of hits (ZINC20592007, ZINC05354646, ZINC20649934, and ZINC39154782) were $0.21 \pm 0.027 \mu\text{M}$, $0.27 \pm 0.064 \mu\text{M}$, $0.3 \pm 0.018 \mu\text{M}$, and $0.28 \pm 0.032 \mu\text{M}$ respectively and were attractive.

Propidium iodide displacement assay

The particular PAS site binding affinity through Trp286 amino acid residue was established by propidium iodide displacement method. The hits successfully displaced propidium, and were selective PAS ligands (Table 10). Molecule ZINC20592007 and ZINC39154782 displaced 100% propidium from PAS of AChE at 3 μM concentration, but ZINC05354646 and ZINC20649934 displaced 57% and 58% respectively, at the same concentration.

In vitro blood–brain barrier permeation assay

A parallel artificial membrane permeation assay of blood–brain barrier (PAMPA-BBB) was performed, as the method described by Di L. *et al.*,²⁷ to explore infiltration of the selected hits into brain. The *in vitro* permeability (P_e) of the four hits (Table 11) and nine commercially available drugs (Table S5, ESI†) was determined through a lipid extract of porcine brain lipid in PBS. The assay was validated by comparing the experimentally obtained permeability [$P_{e(\text{exp})}$] of the nine drugs with reported values of permeation [$P_{e(\text{ref})}$] offering a linear relationship, *i.e.*, $P_{e(\text{exp})} = 1.308 P_{e(\text{literature})} - 0.8394$, ($R^2 = 0.9317$).

The permeability values (P_e) greater than $4.3 \times 10^{-6} \text{ cm s}^{-1}$ were capable of CNS permeability (Fig. S8 & Table S6, ESI†) and the tested compounds demonstrated permeability values above it. Thus, the experimentally determined permeability values (P_e) of the test compounds were a pointer towards their potential to comfortably cross the BBB by passive diffusion.



Fig. 12 RMSF of the protein C- α chain in donepezil–AChE, ZINC20592007–AChE, and ZINC20649934–AChE complexes.






Fig. 13 Schematic diagram of detailed ligand (donepezil, ZINC20592007, and ZINC20649934) interactions with AChE protein amino acid residues after MD simulation.

Cellular cytotoxicity and neuroprotection assessment

The cell viability and neuroprotective potential, against apoptosis of selected hits, were evaluated by utilizing human neuroblastoma SH-SY5Y cell line. To investigate the cytotoxicity of compounds, cells were exposed to considerably high concentrations of the test compounds (50 μ M and 100 μ M) for 24 h. The cell viability was determined by 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The selected compounds showed insignificant cell death even at high concentrations (Table 12). The neuroprotective potential of selected hit molecules was assessed by using L-glutamate as excitotoxicity. In this assay, addition of L-glutamate (100 μ M) to growth media caused significant cell death as was evidenced by reduction in cell viability. The results (Table 12) are mean \pm SEM of at least three independent experiments.

Molecular dynamics (MD) simulation

The analyses of molecular dynamic (MD) simulation of ZINC20592007, ZINC20649934 and donepezil with AChE were performed to establish the binding potency and amino acid residue interactions. In MD simulations, RMSD of the protein backbone C- α atoms and individual inhibitor, Root Mean Square Fluctuation (RMSF) in the individual amino acid side chain and ligand-AChE interactions were recorded concerning time over a period of 50 ns of simulation. The total energy of dynamic ligand-protein complexes was found stable in last 40 ns of entire simulation. Furthermore, temperature, pressure, volume, and potential energy of the complex remained constant, indicating the robustness and reliability of MD simulations. The RMSD of simulation converging between 1.5 and 2.5 Å, denoted the stability of macromolecular ligand-protein complexes during 50 ns simulation. The RMSF in individual amino acid residues during the entire simulation was below 4.0 Å, indicating a lower degree of conformational changes in the side chains.

After initial 10 ns simulation, RMSD of protein backbone C- α along with the ligand RMSD values were stabilized. RMSD plot of RMSD values for protein on the left Y-axis and for ligand these values were displayed on right Y-axis in Fig. 11; protein backbone in green color, and ligand in maroon color. The mean RMSD value for donepezil-AChE complex was 2.04 Å, whereas

ZINC20592007-AChE and ZINC20649934-AChE complexes were 1.76 and 2.11 Å respectively. RMSF was useful for characterizing local changes along the protein chain C- α and peaks indicated areas of the protein that fluctuate the most during the simulation. RMSF values of hits and donepezil were below 4.0 Å, indicated less fluctuation and better stability of ligand-protein complex during simulation (Fig. 12). The interaction of hits with AChE enzyme higher than 30% after MD simulation is provided in Fig. 13.

MD study revealed that ZINC20649934 was interacted Phe 295 with H-bonding through a water molecule, Thr 83 residue with direct H-bonding, and Tyr 341 amino acid with π - π stacking; ZINC20592007 interacted Tyr341, Trp 286, and Phe 295 with H-bond formation through a water molecule, Trp86 with direct H-bonding, and Asp 74 with π - π stacking; and donepezil interacted Trp286, Phe297, and Tyr241 with π - π stacking, and Glu292, and Phe295 with H-bond, and His447 through water involvement H-bonding. MD simulation displayed that all the ligands were interacting with protein at Phe 295 and Trp286, which were present at PAS site of AChE.

Materials and methods

Computational details

The computational tasks, except MD, were performed on an Intel(R) Core (TM) i5-3210M CPU @ 2.50 GHz processor with a memory of 8.0 GB RAM running on a Linux 64 operating system. Schrödinger suite 2015-1 (Schrödinger, LLC, New York, NY, 2015) was utilized to develop structure-based and ligand-based pharmacophore models and for the screening of publicly free 'ZINC15' database. MD simulation was performed using Desmond package on an Intel(R) Xeon(R) CPU E3-1225v5@ 3.30 GHz 3.31 GHz processor, RAM 32.0 GB system with Nvidia 'Quadro P600' GPU running on a Linux 64 operating system.

Development of ligand-based pharmacophore

Total 1062 structurally diverse AChE inhibitors with known and wide range of IC_{50} values (0.043–20 000 nM) were collected from Binding DB database (2017). The LigPrep in Maestro, Schrödinger 2015-1 was utilized to minimize the energy of inhibitor molecules by applying OPLS_2005 force field.²⁸ As,






Fig. 14 Cocrystal ligands structure with PDB id and resolution.

donepezil has mixed type (PAS and CAS site) of binding properties with AChE, therefore, all the compounds were clustered by Tanimoto similarities against donepezil using linear fingerprint descriptors with Canvas v2.3. Compounds were collected depending upon canvas similarity higher than and equal to 0.15 and molecular weight below 500. Finally, 142 inhibitors (Fig. S9 in ESI†) were selected based on Glide docking study at PAS of AChE. The IC_{50} values of inhibitors were converted to pIC_{50} for the generation of 3D-QSAR model. PHASE v4.2, Schrödinger 2015-1 was used to generate 3D-QSAR model.²⁹ The ConfGen, Schrödinger 2015-1 was used to create maximum 1000 number of conformers per structure utilizing force field OPLS_2005. The threshold of actives was above 8.0 and inactives was below 5.7. The PHASE randomly divided all ligands into two sets, *i.e.*, the test set contained 42, and the training set included 100 compounds, to develop an Atom-based 3D-QSAR model in 1.00 Å of grid spacing. The ligands used for development of pharmacophore hypothesis are listed (ESI, Table S7†) with their fitness score, observed pIC_{50} , phase predictive activity, and errors (the difference between observed and predicted activity). The common pharmacophore was obtained from the score of hypotheses having the best alignment of the active set ligands. All 142 compounds were aligned with the template pharmacophore hypothesis of the highly active molecule (Fig. S10 in ESI†).

Validation of ligand-based pharmacophore

The QSAR model was developed with partial least-squares (PLS) factors one to five and was validated by predicting pIC_{50} value of molecules. The QSAR model with PLS factor 5 was considered as the best model. The 3D-QSAR models were externally validated by using LOO method to evaluate the predictivity of hypotheses.^{30,31}

Energy-optimized structure-based pharmacophore generation

Out of total 15, three X-ray crystal structures of hAChE were collected with good resolution and PAS site AChE inhibition activity of cocrystal ligand from the Protein Data Bank (<https://www.rcsb.org>). The cocrystal ligands of three PDB structures *viz.* 4EY7 (donepezil, IC_{50} 5.3 nM), 4M0E (dihydrotanshinone I, K_i 700 nM), and 4M0F (territrem B, IC_{50} 7 nM, & K_i 1.7 nM) are shown in Fig. 14.

Protein structures were prepared using protein preparation wizard in Maestro 10.1, Schrödinger 2015-1 with an OPLS_2005 force field. The Grids of all three PDB structures were prepared at the center of cocrystal ligand using receptor Grid Generation tool in Maestro 10.1, Schrödinger 2015-1. The refined crystal

ligands were docked by utilizing Glide XP (extra precision) docking with corresponding protein structures. The Glide XP energy was ranked by their contribution for the binding of pharmacophoric sites to cocrystal ligand.³² PHASE v4.2, Schrödinger, 2015-1 was applied to generate pharmacophore features based on XP energy descriptor information. It was used to develop pharmacophore sites *viz.* H-bond acceptor (A), H-bond donor (D), hydrophobic group (H), negative ionizable group (N), positive ionizable group (P), and aromatic ring (R). H-bond acceptor and H-bond donor were pointed as vectors, directed to corresponding H-bond donor and acceptor positions at the binding site of receptors respectively. The Glide XP descriptors consisted of hydrophobic enclosure, hydrophobically packed associated hydrogen bonds, electrostatic rewards, π - π stacking, π -cation, and other interactions. The most favorable sites were selected for the development of e-pharmacophore hypothesis by using excluded volume.

Energy-optimized structure-based pharmacophore validation

Enrichment factor (EF) and goodness of hit (GH) were calculated to validate e-pharmacophore hypotheses (eqn (1) and (2) respectively). A dataset of compounds was prepared using 1000 drug-like decoys (http://www.schrodinger.com/glide_decoy_set) with an average molecular weight of 400 D (the “dl-400” dataset) and known actives of 53 AChE inhibitors (inhibitors with IC_{50} less than 100 nM and out of molecules utilized for the 3D-QSAR model), to validate e-pharmacophore models. LigPrep in Schrödinger 2015-1 with Epik was applied to prepare database ligands with an OPLS_2005 force field. EF is the fraction of known actives retrieved after a screening of decoy database compounds.³³

$$EF = \frac{Ha \times D}{Ht \times A} \quad (1)$$

$$GH = \left[\frac{(Ha(3A + Ht))}{4HtA} \right] \left[1 - \frac{(Ht - Ha)}{(D - A)} \right] \quad (2)$$

where, EF = enrichment factor, GH = goodness of hit, D = total compounds in the data set, A = total number of actives in the data set, Ht = total hits, and Ha = active hits.

Pharmacophore-based screening of the database

Only ‘hit-like’ compounds without known AChE inhibitors were collected from ‘ZINC15’ database utilizing Lipinski’s filter. LigPrep with Epik was employed to prepare database ligands utilizing OPLS_2005 force field. One ligand-based pharmacophore and three e-pharmacophores based matched molecules were separately screened against prepared database compounds with PHASE v4.2, Schrödinger 2015-1.³⁴ Pharmacophore matching was required for the most energetically favorable site, and score of more than 1.0 kcal mol⁻¹ was selected for the pharmacophore screening, four sites for hypotheses with 3 or 4 and five sites for hypotheses with 4 or 5 were required to match. The tolerance of distance matching was set up to 2.0 Å. The aligned conformer of molecule matches the hypothesis based on rmsd, site matching, vector alignments,



and volume terms expressed as fitness score.³⁵ The pharmacophore matched database was ranked in order of the fitness score ranging from 0 to 3, as applied in the PHASE. The ligands were selected based on highest fitness scores up to 2000 molecules for each pharmacophore and scores above 1.5 were considered as suitable inhibitors. The molecules with best fitness score were docked into the binding sites of AChE crystal structure.³²

Removal of pan-assay interference compounds (PAINS)

Baell and Holloway reported a list of structural features which generated frequent false positives across screening, known as PAINS.²⁴ Jasial S. *et al.* established a large-scale analysis of behavior of PAINS in biological screening assays.³⁶ The 'ZINC15' database molecules are categorized within (A) anodyne, and (B) clean (PAINS-ok),³⁷ were selected as hits from HTVS retrieves. A KNIME (freely available Konstanz Information Miner, <http://knime.org>)³⁸ workflow distributed with the RDKit³⁹ software package utilizing GUI data analysis platform was developed by Saubern S. *et al.*⁴⁰ The obtained HTVS hits were screened *in silico* for PAINS to avoid false positives in biochemical and pharmacological assays using three public filters, including RDKit,³⁹ ZINC,³⁷ and FAF-Drugs4 server.⁴¹

High throughput virtual screening (HTVS) and molecular docking

Glide HTVS (high throughput virtual screening) is faster than Glide SP and XP, has higher tolerance to suboptimal fits than Glide XP and thus is selected for the study.³³ After removal of PAINS, e-pharmacophore matched compounds were docked into binding sites of respective crystal structures, and ligand-based matched molecules were docked into 4M0E structure with Glide, Schrödinger 2015-1.⁴² The grid was generated at the center position of cocrystal ligand, through Grid Generation tools in Glide. Post-docking MM-GBSA minimization was performed to optimize the ligand geometries. The Glide HTVS screened molecules with best docking scores were selected for Glide SP (standard precision), and XP (extra precision) screenings. Top 10% of retrieves out from each step were taken up for next step. Finally, all the non-peptide retrieves from HTVS and donepezil were docked in Glide XP molecular docking using 4M0E crystal structure (highest resolution PDB with cocrystal ligand, 2.0 Å) to compare the docking score of screened out retrieves with reference donepezil.

Induced fit docking

We applied a mixed molecular docking and dynamics method known as induced fit docking (IFD),⁴³ where the receptor was flexible in docking study. After ADME screening, selected hits were prepared by OPLS_2005 force field utilizing LigPrep. The hits were docked to rigid protein by using Glide, Schrödinger 2015-1 with scaling of ligand van der Waals (vdW) radii 0.5 for nonpolar atoms.⁴⁴ Constrained energy minimization was performed on AChE (PDB: 4M0E) crystal structure, keeping it close to the original crystal structure while removing bad steric contacts. The energy minimization of protein structure was

performed using OPLS_2005 force-field. The Glide XP was utilized for initial docking, and 20 ligand poses were retained for protein structural refinement. Prime, Schrödinger 2015-1 was used to refine residue within 5.0 Å of ligand poses and to generate the induced-fit protein–ligand complexes. Each of the 20 complexes was subjected to refinements of side-chain and backbone,⁴⁴ and were ranked according to Prime energy. The receptor structures within 30 kcal mol^{−1} were redocked for final round of Glide docking and scoring. The Prime refinement included at least one atom of all residue located within 4.0 Å of corresponding ligand pose. In the last step, every ligand was redocked into each refined low-energy receptor structure generated in the refinement step. The new 20 receptor conformations were taken forward for Glide XP redocking. The binding affinity of each complex was reported in the docking score. The more negative docking score indicates more favorable binding with receptor.

Prime MM-GBSA simulation

The free binding energies of highest scoring docked complexes were computed utilizing molecular mechanic-generalized Born surface area (MM-GBSA)⁴⁵ followed by default parameters. Based on the docking score and MM/GBSA binding-free energy, Jin *et al.* developed correlation model between docking scores or calculated binding-free energies and experimental pIC₅₀ values.⁴⁶ The Prime (Maestro v10.1, Schrödinger, LLC, New York, NY, 2015) was employed to calculate the MM-GBSA energy of Glide XP docked complex. The OPLS_2005 force field in conjunction with GBSA continuum model⁴⁷ was utilized to determine energies of selected complexes of ligands. Computationally, the binding free energies (ΔG_{bind}) of ligands were calculated using the following equation.⁴⁸

$$\Delta G_{\text{bind}} = \Delta E_{\text{MM}} + \Delta G_{\text{solv}} + \Delta G_{\text{SA}}$$

where ΔE_{MM} is the difference between minimized energies of the AChE-inhibitor complex and sum of the minimized energies of unliganded AChE and its inhibitor, ΔG_{solv} is difference between GBSA solvation energies of enzyme–inhibitor complex and sum of the GBSA solvation energies of unliganded AChE and inhibitor, and ΔG_{SA} is the difference between surface area energies of the complex and sum of the surface area of unliganded enzyme and its inhibitor.

Docking using Autodock

AutoDockTools-1.5.6. and AutoDock 4.2 suite were utilized to redock the selected hits as AChE inhibitor for comparison of the Glide XP docking, IFD, and AutoDock results. AChE crystal structure, 4M0E, was prepared using AutoDock Tools. Atom charges, solvation parameters, and polar hydrogens were added to enzyme structure for docking simulation before applying to PDBQT file format. The Chem3D 16.0 chemical structure drawing software was utilized to draw hits with standard 3D structures and to minimize energies of the compounds using MM2 energy minimization method.⁴⁹ The AutoDock 4.2 ligand optimization was performed using Gasteiger charges



optimization, non-polar hydrogens were merged, and saved as PDBQT file. AutoDock requires pre-calculated grid maps, and the grid must surround the region of active site of AChE. Therefore, the grid box was centered at the active site including Leu 289, Arg 296, Phe 297, Phe 338, Trp 286, Ser 293, Val 294, Phe 295, Tyr 72, Tyr 341, Asp 74, Tyr 124 and Tyr 337 amino acid residues. The grid box size was positioned at 40, 42, and 48 Å and the grid center was set to 20.683, −16.615, 19.006 for x, y and z respectively, covering the active pocket. AutoGrid 4.0 was used to produce a grid with 0.375 Å spacing between grid points. The Lamarckian Genetic Algorithm (LGA) was used to search best conformers, and a maximum of 50 conformers was considered for each compound with the default setting. The Discovery Studio Visualizer was used for visualization of interactions. AutoDock Tools provided various methods for analyzing the results of docking simulations, *viz.* conformational similarity, visualizing the binding site and its energy, intermolecular energy and inhibition constant.

ADME properties prediction

The QikProp in Maestro 10.1, Schrödinger 2015-1 (ref. 50) was used to predict ADME properties of hit molecules. As the QikProp was unsuitable to neutralize the compounds and generate the descriptors, in the normal mode, hence, neutralization of all molecules was essential before performing QikProp. The QikProp predicted physicochemically significant and pharmaceutically applicable 44 descriptors for the hits. These included principle descriptors, physiochemical properties as well as log *P* (octanol/water), QP%, log HERG, Caco-2 cell membrane permeability, MDCK cell permeability, skin permeability log *K_p* and Lipinski's rule of five, which were crucial for rational drug design.^{51,52}

Density functional theory

Density functional theory (DFT) is utilized to determine and validate enzymatic reaction mechanisms and the enzyme active sites. Electronic effects of drug-like compounds play an essential role in the pharmacological effects.⁵³ The most and least active AChE inhibitors of training set were optimized with the final hits in Jaguar (Jaguar v8.7, Schrödinger, LLC, New York, NY, 2015) program utilizing Lee–Yang–Parr correlation functional (B3LYP) theory, and Becke's three-parameter exchange potential^{54,55} with 6-31G* basis set. The molecular orbital surfaces, atomic electrostatics potential charges (EPS) and molecular electrostatic potential (MESP) were determined to calculate the HOMO and LUMO. The HOMO energy of small ligand molecules can donate electrons during the drug–enzyme complex formation, while LUMO energy manifests the capacity of the molecule to accept the electrons from the protein. The HOMO–LUMO gap energy (difference in HOMO and LUMO energy), expresses the electronic excitation energy, that is essential to compute the molecular reactivity and stability of the drug–protein complex.²⁵

In silico AChE selectivity study

To determine binding affinity of hits towards BuChE, we carried out XP docking of hits using crystal structure of 4BDS (highest resolution PDB of human BuChE, 2.1 Å). The Glide (Glide, Schrödinger, LLC, New York, NY, 2015) was used to perform Glide XP docking in default setting for all docking steps, and the Grid was centralized at the PAS site of BuChE *i.e.*, centralized the residues Asp70, Trp 82, Asn83, Ser198, and Tyr332.⁵⁶

In vitro AChE and BuChE enzyme inhibition

The AChE and BuChE inhibition studies were performed by Ellman *et al.* method.²⁶ Four selected hit molecules (ZINC20592007, ZINC05354646, ZINC20649934, and ZINC39154782) out of ten, were procured from MolPort SIA, Riga, Latvia (MolPort id: MolPort-002-672-705, MolPort-002-658-497, MolPort-005-915-644, and MolPort-004-876-009 respectively). The AChE from *Electrophorus electricus* and BuChE from horse serum (lyophilized powder) (CAS No. 9000-81-1, CAS No. 9001-08-5, respectively) were purchased from Sigma Aldrich, India. Acetylthiocholine iodide (ATCI), butyrylthiocholine iodide (BTCl), 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB–Ellman's reagent) and phosphate buffer saline (PBS), pH 7.4 were procured from HiMedia Laboratories, India, and donepezil (Sigma Aldrich, India) was used as reference. Six different concentrations (75 µM, 15 µM, 7.5 µM, 3 µM, 0.6 µM, and 0.12 µM) of hits, 0.25 mM DTNB, 0.06 unit mL^{−1} of AChE or BuChE were combined in PBS and incubated at 37 °C for 30 min to determine inhibition of AChE or BuChE. 0.36 mM of the substrate (ATCI or BTCl) was added to reaction mixture before measuring absorbance at 415 nm wavelength by Synergy HTX multi-mode reader (BioTek, USA). The process was performed in triplicate with a blank and control, to calculate the percentage inhibition due to selected hits. The IC₅₀ values, *i.e.*, the concentration of the drug resulting in 50% inhibition of enzyme activity, were determined graphically from inhibition curves (log inhibitor concentration *vs.* percent inhibition) utilizing GraphPad Prism 5.0, GraphPad Software Inc.⁵⁷

The enzyme kinetics (the mechanism of inhibition by ligands) of were determined by previously described method.²⁶ Eight concentrations of substrate (ATCI; 0.1–1.15 µM) were incubated with AChE in absence and presence of different concentrations of test molecules (0.25 µM, 0.5 µM & 1 µM for ZINC20592007, and ZINC05354646; and 0.5 µM, 1 µM & 2 µM for ZINC20649934, and ZINC39154782). The absorbance was measured for 30 min at intervals of 5 min at 415 nm wavelength. The products formed during the time frame of 30 min were estimated by Beer–Lambert law. *V_{max}* and *K_m* values of Michaelis–Menten kinetics were computed by nonlinear regression from substrate–velocity curves using GraphPad Prism 5. Linear regression was used to calculate inhibition constant (*K_i*) utilizing Lineweaver–Burk plots.⁵⁸ *K_i* value was determined by Yonetani–Theorell method in which the lines from the double reciprocal Lineweaver–Burk plot were extrapolated to intersect at a point.⁵⁹ The positive reciprocal x-values of intersecting point were the determined *K_i* value



of hits. The enzyme kinetics assays were performed in triplicate.

Assay of propidium iodide displacement

The molecular modeling studies illustrated that selected hits were PAS selective AChE inhibitors. Propidium iodide is a specific PAS selective ligand, which displays 10-fold fluorescence enrichment when bound to AChE. The displacement by hits was measure of their affinity towards PAS of AChE. Three concentrations (0.24, 1.0, and 3.0 μM) of test compounds, 5 μM AChE from electric eel (eeAChE) in PBS, pH 7.4, were added in black 96-well plates and were kept at room temperature for 6 h.⁶⁰ The sample solutions were incubated for 15 min with 20 μM of propidium iodide (HiMedia, India), and intensity of fluorescence was measured in excitation and emission modes at 485 and 620 nm, respectively. The assay was carried out in triplicate.

In vitro blood–brain barrier permeation assay

The possible *in vitro* blood–brain barrier (BBB) permeation of compounds was predicted by parallel artificial membrane permeation assay (PAMPA) of BBB as described by Di L. *et al.*²⁷ The donor microplates (PVDF membrane, pore size 0.45 μm) and acceptor microplates were obtained from Millipore, Bengaluru, India. The filter surface of donor microplate was impregnated with 4 μL of 20 mg mL^{-1} porcine brain lipid (Avanti polar lipids, Alabaster) in dodecane (Avra Synthesis, Hyderabad, India), and the acceptor microplates were filled with 200 μL of PBS, pH 7.4. 5 mg mL^{-1} of test compounds were dissolved in DMSO and diluted with PBS to obtain a final concentration of 100 $\mu\text{g mL}^{-1}$. The donor well plates were filled with 200 μL of test solution and were carefully placed on the acceptor plate like a sandwich, carrying it undisturbed for 18 h at 25 $^{\circ}\text{C}$. The donor plates were then removed, and concentration of compounds in acceptor, and donor wells were determined by measuring absorbance. Each well was analyzed at five different wavelengths with three independent performances, and results were explicit as mean \pm SEM. The nine commercial drugs with known BBB permeability (verapamil, diazepam, progesterone, atenolol, dopamine, lomefloxacin, alprazolam, chlorpromazine, and oxazepam) were utilized to validate PAMPA model. The above-described method was followed to determine the experimental permeability, $\text{Pe}_{(\text{exp})}$ values of these drugs, and data were regressed against $\text{Pe}_{(\text{ref})}$ from literature to establish a linear correlation.⁶¹

Determination of cellular cytotoxicity and neuroprotection

Neuronal cell line cultures. The human neuroblastoma SH-SY5Y cell line was procured from National Centre for Cell Science (NCCS) Pune, India. Cells were cultured into T25 flasks containing Dulbecco's modified Eagle's medium nutrient mixture F-12 (DMEM-F12), supplemented with 10% fetal bovine serum (FBS), 1 μM glutamine, 50 U mL^{-1} penicillin, and 50 $\mu\text{g mL}^{-1}$ streptomycin and were maintained at 37 $^{\circ}\text{C}$ in 5% CO_2 humidified air. For MTT assay and neuroprotection study, SH-

SY5Y cells were subcultured in 96-well plates at seeding density of 5×10^4 cells per well.

Determination of cell viability and neuroprotection. The MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay⁶² was performed to determine cytotoxicity of selected hits. After 24 h incubation at 37 $^{\circ}\text{C}$, the medium was changed with test compounds having concentrations of 50 μM and 100 μM , for another 24 h at previously described conditions. 5 mg mL^{-1} of MTT (Sigma-Aldrich, India) in PBS was added to the culture medium for 4 h at 37 $^{\circ}\text{C}$. The medium was removed, and the blue formazan crystals formed were dissolved in DMSO and evaluated by measuring absorbance at 570 nm. The test was carried out in triplicate, and results were explicit as mean \pm SEM.

Neuroprotectivity of selected hits was determined by evaluating their ability to protect SH-SY5Y cells against induced apoptosis by L-glutamate excitotoxicity. Amyloid beta ($\text{A}\beta$) neurotoxicity was triggered by L-glutamate in SH-SY5Y cell line.⁶³ The cells were treated with test compounds, at 25 μM concentration, and incubated for 2 h. After incubation, cells were treated with a medium containing 100 μM of L-glutamate and left for an additional 24 h. The cell viability, after the treatment of L-glutamate, was assessed by MTT assay. The medium was further replaced with 80 μL of fresh medium and 20 μL of MTT (0.5 mg mL^{-1}) in PBS. After 4 h of incubation, MTT solution was removed, and the crystals of formazan were dissolved in DMSO to measure the absorbance at 570 nm. Percentage of neuronal cell protection against L-glutamate was calculated by considering the absorbance of the control cells as 100% of the cell viability.

Molecular dynamics (MD) simulation

MD simulations of ZINC20592007 (most active in *in vitro* tests and 100% PAS selective), ZINC20649934 (higher docking score in *in silico* and 58% PAS selective in *in vitro*), and donepezil were performed utilizing Desmond v2.2, Schrödinger 2015-1 with the OPLS 2005 force field to model all peptide interactions,^{64,65} and TIP3P (transferable intermolecular potential with 3 points) model was used for solvent. Protein–ligand docked complex (.pv file) from XP docking was taken for solvation using open TIP3P water model in an orthorhombic core box of 20 Å radius. The overall complex had six negative charges and was neutralized by adding Na^+ counter ion for simulation. Ligand–protein complex was minimized by steepest descent method followed by BFGS (Broyden–Fletcher–Goldfarb–Shanno) algorithm having a convergence threshold of 2.0 kcal mol^{-1} and 41 667 iterations. Ewald method (PME)⁶⁶ was used to calculate long-range electrostatic interactions with a grid spacing of 0.8. van der Waals and short-range electrostatic interactions were truncated at 9.0. Nose–Hoover thermostats⁶⁷ were utilized to maintain constant simulation temperature, and Martina–Tobias–Klein method⁶⁸ was used to control pressure throughout simulation. The equations of motion were integrated utilizing the multistep RESPA integrator⁶⁹ with an internal time step of 2.0 fs for bonded interactions and non-bonded interactions within 6.0 fs cut off. MD



simulations were conceded out at 300 K temperature and 1.01325 bar pressure. The overall model system was relaxed for 2 ns before a 50 ns simulation, and coulombic interactions were defined by a short-range cut off radius of 9.0 Å and by a long-range smooth particle mesh Ewald tolerance to 1×10^{-9} . Further, for energy calculation and trajectory analysis, recording interval of 1.2 ps was defined.

Conclusions

A 3D-QSAR and three e-pharmacophore models were developed from known AChE inhibitors, structurally similar to donepezil and available AChE crystal structures with cocrystal ligand at PAS site. Virtual screening of ZINC15 compounds afforded new excellent, non-toxic AChE inhibitors. The hits interacted with Trp 286, Phe 295, Asp 74, Tyr 337, and Tyr 124 residues of AChE crystal structure through one to three H-bond(s) and one to three pi-pi stacking interaction(s). MD strongly supported that the identified hits bound at PAS of AChE only. *In vitro* enzyme assays, with propidium iodide displacement of ZINC20592007, ZINC05354646, ZINC20649934, and ZINC39154782, also supported the *in-silico* results. ZINC20592007 and ZINC39154782, interacting with Try 286 amino acid residue, provided 100% propidium displacement at 3 μM concentration. The PAS site-selective mimics responded to inhibition of amyloid formation. The hits had attractive K_i values ($0.21 \pm 0.027 \mu\text{M}$, $0.27 \pm 0.064 \mu\text{M}$, $0.3 \pm 0.018 \mu\text{M}$, and $0.28 \pm 0.032 \mu\text{M}$) with insignificant toxicity against neuroblastoma SH-SY5Y cell, good BBB permeability, and neuroprotectivity against L-glutamate induced excitotoxicity.

Further, ZINC20592007 molecule had potent, selective AChE inhibition at PAS, *i.e.*, non-competitive, CNS permeability, non-toxicity, neuroprotectivity, and A β formation and aggregation inhibition, which increased cholinergic activity and also prevented A β aggregation to control AD. We consider that these compounds are excellent candidates to develop further as leads for AChE inhibition.

Conflicts of interest

The authors declare no competing financial interest.

Abbreviations

AChE	Acetylcholinesterase
AChEI	AChE inhibitor
AD	Alzheimer's disease
ADME	Absorption distribution metabolism and excretion
APP	Amyloid precursor protein
BBB	Blood brain barrier
BuChE	Butyrylcholinesterase
CNS	Central nervous system
3D-QSAR	3-Dimensional-quantitative structure activity relationship
EF	Enrichment factor

e-pharmacophore	Energy-optimized pharmacophore
Glide XP	Glide extra precision
GH	Goodness of hit
HTVS	High throughput virtual screening
IFD	Induced fit docking
MD	Molecular dynamics
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
OPLS	Optimized potential for liquid simulations
PAINS	Pan assay interference compounds
PAMPA	Parallel artificial membrane permeation assay
RMSD	Root mean square deviation
SP	Standard precision
THA	Tacrine
1YL	(1R)-1,6-Dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione

Acknowledgements

The authors are thankful to Department of Biotechnology, Ministry of Science & Technology, New Delhi, India for financial support (BT/PR9624/MED/30/1253/2013 dated-29/11/2014). We are grateful to Dr Ozair Alam, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India, for his assistance and support. S. J. and A. G. would like to thank Ministry of Human Resource Development, New Delhi, India, for the award of senior research fellowships to them.

References

- 1 Y. Bourne, P. Taylor, P. E. Bougis and P. Marchot, *J. Biol. Chem.*, 1999, **274**, 2963–2970.
- 2 G. Johnson and S. Moore, *Curr. Pharm. Des.*, 2006, **12**, 217–225.
- 3 H. Soreq and S. Seidman, *Nat. Rev. Neurosci.*, 2001, **2**, 294–302.
- 4 M. Pakaski and P. Kasa, *Curr. Drug Targets: CNS Neurol. Disord.*, 2003, **2**, 163–171.
- 5 N. P. L. Verhoeff, *Expert Rev. Neurother.*, 2005, **5**, 277–284.
- 6 J. Massoulié, J. Sussman, S. Bon and I. Silman, *Prog. Brain Res.*, 1993, **98**, 139–146.
- 7 J. Massoulié and S. Bon, *Annu. Rev. Neurosci.*, 1982, **5**, 57–106.
- 8 E. O. Campos, A. Alvarez and N. C. Inestrosa, *Neurochem. Res.*, 1998, **23**, 135–140.
- 9 N. C. Inestrosa, A. Alvarez, C. A. Perez, R. D. Moreno, M. Vicente, C. Linker, O. I. Casanueva, C. Soto and J. Garrido, *Neuron*, 1996, **16**, 881–891.
- 10 M.-S. García-Ayllón, D. H. Small, J. Avila and J. Sáez-Valero, *Front. Mol. Neurosci.*, 2011, **4**, 22.
- 11 F. Ferreri, C. Agboku and S. Gauthier, *J. Psychiatry Neurosci.*, 2006, **31**, 369.
- 12 S. R. Ribeiz, D. P. Bassitt, J. A. Arrais, R. Avila, D. C. Steffens and C. M. Bottino, *CNS Drugs*, 2010, **24**, 303–317.
- 13 A. A. Kehagia, R. A. Barker and T. W. Robbins, *Lancet Neurol.*, 2010, **9**, 1200–1213.



- 14 T. Brenner, Y. Hamra-Amitay, T. Evron, N. Boneva, S. Seidman and H. Soreq, *FASEB J.*, 2003, **17**, 214–222.
- 15 T. Brenner, E. Nizri, M. Irony-Tur-Sinai, Y. Hamra-Amitay and I. Wirguin, *J. Neuroimmunol.*, 2008, **201**, 121–127.
- 16 E. Giacobini, *Int. J. Geriatr. Psychiatry*, 2003, **18**, S1–S5.
- 17 S. Jana and S. K. Singh, *J. Biomol. Struct. Dyn.*, 2018, 1–22.
- 18 J. K. Dhanjal, S. Sharma, A. Grover and A. Das, *Biomed. Pharmacother.*, 2015, **71**, 146–152.
- 19 P. Ambure, S. Kar and K. Roy, *BioSystems*, 2014, **116**, 10–20.
- 20 G. Brahmachari, C. Choo, P. Ambure and K. Roy, *Bioorg. Med. Chem.*, 2015, **23**, 4567–4575.
- 21 Y. Zhang, S. Zhang, G. Xu, H. Yan, Y. Pu and Z. Zuo, *Mol. Biosyst.*, 2016, **12**, 3734–3742.
- 22 S. Bag, R. Tulsan, A. Sood, S. Datta and M. Torok, *Curr. Comput.-Aided Drug Des.*, 2013, **9**, 2–14.
- 23 R. Malik, B. S. Choudhary, S. Srivastava, P. Mehta and M. Sharma, *J. Biomol. Struct. Dyn.*, 2016, 1–17.
- 24 J. B. Baell and G. A. Holloway, *J. Med. Chem.*, 2010, **53**, 2719–2740.
- 25 Y. Zheng, M. Zheng, X. Ling, Y. Liu, Y. Xue, L. An, N. Gu and M. Jin, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 3523–3530.
- 26 G. L. Ellman, K. D. Courtney, V. Andres Jr and R. M. Featherstone, *Biochem. Pharmacol.*, 1961, **7**, 88–95.
- 27 L. Di, E. H. Kerns, K. Fan, O. J. McConnell and G. T. Carter, *Eur. J. Med. Chem.*, 2003, **38**, 223–232.
- 28 Schrödinger, LLC, *S. Release*, New York, NY, 2015.
- 29 S. L. Dixon, A. M. Smondyrev and S. N. Rao, *Chem. Biol. Drug Des.*, 2006, **67**, 370–372.
- 30 P. Pratim Roy, S. Paul, I. Mitra and K. Roy, *Molecules*, 2009, **14**, 1660–1701.
- 31 K. Loving, N. K. Salam and W. Sherman, *J. Comput.-Aided Mol. Des.*, 2009, **23**, 541–554.
- 32 N. K. Salam, R. Nuti and W. Sherman, *J. Chem. Inf. Model.*, 2009, **49**, 2356–2368.
- 33 T. A. Halgren, R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Frye, W. T. Pollard and J. L. Banks, *J. Med. Chem.*, 2004, **47**, 1750–1759.
- 34 J. J. Irwin, T. Sterling, M. M. Mysinger, E. S. Bolstad and R. G. Coleman, *J. Chem. Inf. Model.*, 2012, **52**, 1757–1768.
- 35 S. L. Dixon, A. M. Smondyrev, E. H. Knoll, S. N. Rao, D. E. Shaw and R. A. Friesner, *J. Comput.-Aided Mol. Des.*, 2006, **20**, 647–671.
- 36 S. Jasial, Y. Hu and J. r. Bajorath, *J. Med. Chem.*, 2017, **60**, 3879–3886.
- 37 T. Sterling and J. J. Irwin, *J. Chem. Inf. Model.*, 2015, **55**, 2324–2337.
- 38 M. R. Berthold, N. Cebron, F. Dill, T. Gabriel, T. Kötter, T. Meinl, P. Ohl, C. Sieb, K. Thiel and B. Wiswedel, *Data Analysis, and Knowledge Organisation (GfKL 2007)*, Springer, 2007.
- 39 G. Landrum, *RDChEMBL*, 2013.
- 40 S. Saubern, R. Guha and J. B. Baell, *Mol. Inf.*, 2011, **30**, 847–850.
- 41 D. Lagorce, L. Bouslama, J. Becot, M. A. Miteva and B. O. Villoutreix, *Bioinformatics*, 2017, **33**, 3658–3660.
- 42 R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin and D. T. Mainz, *J. Med. Chem.*, 2006, **49**, 6177–6196.
- 43 H. Wang, R. Aslanian and V. S. Madison, *J. Mol. Graphics Modell.*, 2008, **27**, 512–521.
- 44 R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley and J. K. Perry, *J. Med. Chem.*, 2004, **47**, 1739–1749.
- 45 N. Huang, C. Kalyanaraman, J. J. Irwin and M. P. Jacobson, *J. Chem. Inf. Model.*, 2006, **46**, 243–253.
- 46 M. Jin, N. Shepardson, T. Yang, G. Chen, D. Walsh and D. J. Selkoe, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 5819–5824.
- 47 Z. Yu, M. P. Jacobson and R. A. Friesner, *J. Comput. Chem.*, 2006, **27**, 72–89.
- 48 P. D. Lyne, M. L. Lamb and J. C. Saeh, *J. Med. Chem.*, 2006, **49**, 4805–4808.
- 49 G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew and A. J. Olson, *J. Comput. Chem.*, 1998, **19**, 1639–1662.
- 50 E. M. Duffy and W. L. Jorgensen, *J. Am. Chem. Soc.*, 2000, **122**, 2878–2888.
- 51 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, *Adv. Drug Delivery Rev.*, 1997, **23**, 3–25.
- 52 F. Ntie-Kang, *SpringerPlus*, 2013, **2**, 353.
- 53 J. Matysiak, *Eur. J. Med. Chem.*, 2007, **42**, 940–947.
- 54 P. M. Gill, B. G. Johnson, J. A. Pople and M. J. Frisch, *Chem. Phys. Lett.*, 1992, **197**, 499–505.
- 55 P. Stephens, F. Devlin, C. Chabalowski and M. J. Frisch, *J. Phys. Chem.*, 1994, **98**, 11623–11627.
- 56 P. Masson, W. Xie, M.-T. Froment, V. Levitsky, P.-L. Fortier, C. Albaret and O. Lockridge, *Protein Struct. Mol. Enzymol.*, 1999, **1433**, 281–293.
- 57 H. Motulsky, *GraphPad Software*, 2007, vol. 31, pp. 39–42.
- 58 Y. Wang, X.-L. Guan, P.-F. Wu, C.-M. Wang, H. Cao, L. Li, X.-J. Guo, F. Wang, N. Xie and F.-C. Jiang, *J. Med. Chem.*, 2012, **55**, 3588–3592.
- 59 R. A. Copeland, *Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists*, John Wiley & Sons, 2013.
- 60 J. Eichler, A. Anselment, J. L. Sussman, J. Massoulié and I. Silman, *Mol. Pharmacol.*, 1994, **45**, 335–340.
- 61 D. Kumar, S. K. Gupta, A. Ganeshpurkar, G. Gutti, S. Krishnamurthy, G. Modi and S. K. Singh, *Eur. J. Med. Chem.*, 2018, **150**, 87–101.
- 62 J. van Meerloo, G. J. L. Kaspers and J. Cloos, in *Cancer Cell Culture: Methods and Protocols*, ed. I. A. Cree, Humana Press, Totowa, NJ, 2011, pp. 237–245, DOI: 10.1007/978-1-61779-080-5_20.
- 63 X. Di, J. Yan, Y. Zhao, J. Zhang, Z. Shi, Y. Chang and B. Zhao, *Neuroscience*, 2010, **168**, 778–786.
- 64 W. L. Jorgensen, D. S. Maxwell and J. Tirado-Rives, *J. Am. Chem. Soc.*, 1996, **118**, 11225–11236.
- 65 G. A. Kaminski, R. A. Friesner, J. Tirado-Rives and W. L. Jorgensen, *J. Phys. Chem. B*, 2001, **105**, 6474–6487.



- 66 U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee and L. G. Pedersen, *J. Chem. Phys.*, 1995, **103**, 8577–8593.
- 67 W. G. Hoover, *Phys. Rev. A: At., Mol., Opt. Phys.*, 1985, **31**, 1695.
- 68 G. J. Martyna, D. J. Tobias and M. L. Klein, *J. Chem. Phys.*, 1994, **101**, 4177–4189.
- 69 S. J. Basha, P. Mohan, D. P. Yeggoni, Z. R. Babu, P. B. Kumar, A. D. Rao, R. Subramanyam and A. G. Damu, *Mol. Pharm.*, 2018, **15**, 2206–2223.

